Humate-P®. Antihemophilic Factor/von Willebrand Factor Complex (Human) 1 INDICATIONS AND USAGE 1.1 Hemophilia A. Humate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human), is indicated for treatment and prevention of bleeding in adults with hemophilia A (classical hemophilia).
Alphanate, Humate P (antihemophilic factor/von Willebrand Humate P: Adequate and well-controlled studies with long-term evaluation of joint damage have not been done. Wilate. Indicated for adolescents with hemophilia A as routine prophylaxis to reduce the frequency of bleeding episodes and for on-demand treatment and control of bleeding episodes; On-demand hemorrhage treatment Humate-P® This document applies to all Covenant and AHS … Humate-P® is a stable, lyophilized concentrate of Antihemophilic factor and von Willebrand Factor (vWF) purified from pooled human fresh-frozen plasma. Virally reduced by pasteurization. Humate-P® has a high degree of purity with a low amount of non-factor proteins. How Humate Works
Humate-P antihemophilic factor/vwf. This product contains human factor VIII (also called antihemophilic factor) and von Willebrand factor complex. Factors are proteins normally found in the blood that help the blood to thicken (clot) and stop any bleeding. People with low levels of factor VIII and von Willebrand factor are at risk for bleeding
How to use Humate-P Human Kit. This medication is given by injection into a vein, usually over 5 to 10 minutes or as directed by your doctor. The medication may need to be given more slowly over a
Humate-P: Indications, Side Effects, Warnings - Drugs.com
Humate-P: 55,200 billable units per 28 day supply Wilate: 34,500 billable units per 90 day supply III. Initial Approval Criteria Hemophilia Management Program Requirements for half-life study and inhibitor tests are a part of the hemophilia management program. Evidence-Based Clinical Decision Support at the Point of UpToDate helps hospitals meet rigorous quality standards . Now, more than ever, healthcare providers are challenged to implement resources and tools with a proven positive impact on patient outcomes, safety, and experience, while also reducing costs through enhancements and efficiencies.. Research confirms that use of UpToDate is one of the most effective approaches for improving healthcare Efficacy and safety of the factor VIII/von Willebrand The present study was initiated to evaluate the safety and efficacy of Haemate-P (Humate-P in North America) (anti-hemophilic FVIII/VWF complex [human] dried, pasteurized) dosed in ristocetin cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada. Alphanate, Humate-P, Koate-DVI, Wilate